Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3323 ARTÍCULOS , VIENDO DEL 2416 AL 2430

Polyglutamine misfolding in yeast: toxic and protective aggregation

Duennwald ML.

Prion. 2011 Oct-Dec;5(4):285-90. doi: 10.4161/pri.18071. Epub 2011 Oct 1.

Parkinsonism: heterogeneity of a common neurological syndrome

Bohlhalter S, Kaegi G.

Swiss Med Wkly. 2011 Nov 1;141:w13293. doi: 10.4414/smw.2011.13293. eCollection 2011.

Dynamic modeling of α-synuclein aggregation in dopaminergic neuronal system indicates points of neuroprotective intervention: experimental validation with implications for Parkinson's therapy

Sultana Z, Paleologou KE, Al-Mansoori KM, Ardah MT, Singh N, Usmani S, Jiao H, Martin FL, Bharath MM, Vali S, El-Agnaf OM.

Neuroscience. 2011 Dec 29;199:303-17. doi: 10.1016/j.neuroscience.2011.10.018. Epub 2011 Oct 20.

Premotor symptoms and early diagnosis of Parkinson's disease

Adler CH.

Int J Neurosci. 2011;121 Suppl 2:3-8. doi: 10.3109/00207454.2011.620192.

Nonmotor symptoms in Parkinson's disease

Stacy M.

Int J Neurosci. 2011;121 Suppl 2:9-17. doi: 10.3109/00207454.2011.620196.

The evidence for disease modification in Parkinson's disease

Lew MF.

Int J Neurosci. 2011;121 Suppl 2:18-26. doi: 10.3109/00207454.2011.620194.

Diagnosis and initiation of treatment in Parkinson's disease

Lyons KE, Pahwa R.

Int J Neurosci. 2011;121 Suppl 2:27-36. doi: 10.3109/00207454.2011.620197.

Motor complications in Parkinson's disease

Ondo WG.

Int J Neurosci. 2011;121 Suppl 2:37-44. doi: 10.3109/00207454.2011.620198.

Pharmacologic safety concerns in Parkinson's disease: facts and insights

Chen JJ.

Int J Neurosci. 2011;121 Suppl 2:45-52. doi: 10.3109/00207454.2011.620193.

Future treatments for Parkinson's disease: surfing the PD pipeline

Hauser RA.

Int J Neurosci. 2011;121 Suppl 2:53-62. doi: 10.3109/00207454.2011.620195.

Long-term consequences of repetitive brain trauma: chronic traumatic encephalopathy

Stern RA, Riley DO, Daneshvar DH, Nowinski CJ, Cantu RC, McKee AC.

PM R. 2011 Oct;3(10 Suppl 2):S460-7. doi: 10.1016/j.pmrj.2011.08.008.

Initial motor symptoms of Parkinson disease

Garcia Ruiz PJ, Catalán MJ, Fernández Carril JM.

Neurologist. 2011 Nov;17(6 Suppl 1):S18-20. doi: 10.1097/NRL.0b013e31823966b4.

Assessment of Parkinson disease: what do we need to show neuroprotection?

Ybot-Gorrin I, Vivancos-Matellano F, Chacón-Peña JR, Alonso-Navarro H, Jiménez-Jiménez FJ.

Neurologist. 2011 Nov;17(6 Suppl 1):S21-9. doi: 10.1097/NRL.0b013e31823966c6.

Sleep disorders in Parkinson disease

Iranzo de Riquer A, Bergareche A, Campos V.

Neurologist. 2011 Nov;17(6 Suppl 1):S38-42. doi: 10.1097/NRL.0b013e31823966f8.

Treatment of Parkinson disease, time and dosage: "does simple dosage facilitate compliance and therapeutic goals?"

Sesar A, Arbelo JM, del Val JL.

Neurologist. 2011 Nov;17(6 Suppl 1):S43-6. doi: 10.1097/NRL.0b013e31823968d3.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias